Breaking News

Thermo Fisher Buys GSK API Site for $100M

Expands complex API manufacturing footprint with acquisition of site in Ireland

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Thermo Fisher Scientific has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline for approximately $100 million (~€90mn). The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs).   With more than 400 employees, the site produces highly specialized APIs for treating diseases including childhood cancer, depression and Parkinso...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters